🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

26 results for “protocol” Clear

  1. RBC transfusion based on different protocols

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Transfusion Related Complication

    phase 3 other active

    1 trial

  2. TARGET protocol EN 1.5 kcal/mL

    Zealand Pharma A/S

    Critical Illness

    phase 3 other completed

    1 trial

  3. Tecentriq 1 200 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Cancer (Future parent protocols may include other cancer that are not included in this section)

    phase 3 small molecule active

    1 trial

  4. Unified protocol for adolescents (UP-A)

    Chinese University of Hong Kong

    Depressive Disorder

    phase 3 other completed

    1 trial

  5. BZD discontinuation protocol

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Use Disorders

    phase 2 small molecule completed

    1 trial

  6. NKTR-214

    Nektar Therapeutics UK Limited

    Unspecified Adult Solid Tumor, Protocol Specific

    phase 2 small molecule completed

    1 trial

  7. Placebo tablets are produced with the same appearance as the Valganciclovir tablets, with the same content except for the active compound., VALGANCICLOVIR

    The George Institute

    Glioblstoma WHO grade IV

    phase 2 small molecule active

    1 trial

  8. Rilvegostomig, Rilvegostomig

    AstraZeneca AB

    Advanced Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, stage III unresectable Non-small Cell Lung Cancer (Protocol Parts A-B), stage IV Non-small Cell Lung Cancer (Protocol Parts A-E).

    phase 2 small molecule active

    1 trial

  9. Study evaluating the efficacy of the treatment after targeting PD-L1 and TIGIT in tumors with tertiary lymphoid structures

    The George Institute

    Adult patients with a histologically confirmed TLS-positive advanced or metastatic NSCLC naïve from systemic treatment or previously treated with chemotherapy and PD1/PDL1 antagonist, and not having previously been treated with CD137 agonists or investigational immune checkpoint blockade therapies, including (but not limited) anti-TIGIT, anti-LAG3. Patients must have adequate organ function with a performance status (WHO 0-1; ECOG 0-1). Patients must not have active or history of autoimmune disease or immune deficiency. The pregnant or breastfeeding women will be excluded. Other eligibility criteria are described in the related section of the protocol.

    phase 2 other active

    1 trial

  10. The Modular Protocol for Mental Health

    COGNITION THERAPEUTICS INC

    Major Depressive Disorder

    phase 2 other completed

    1 trial

  11. Varenicline Adaptive Protocol

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    phase 2 small molecule completed

    1 trial

  12. A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-Human Study of Orally Administered DF-006 to Evaluate the Safety, Tolerability, and Pharmacokinetics After a Single Dose and Multiple Doses of Orally Administered DF-006 in Healthy Subjects (Part 1 and Part 2) and in Chronic Hepatitis B Patients (Part 3). Protocol Number Df-006-1001

    Wuhan Createrna Science and Technology Co., Ltd

    Chronic Hepatitis B

    phase 1 other active

    1 trial

  13. AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)

    Amgen

    Thoracic tumors with homozygous MTAP-deletion

    phase 1 other active

    1 trial

  14. AMG 193 in Combination with Other Therapies in Subjects with Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous MTAP-deletion – Master Protocol

    Amgen

    Gastrointestinal tract, biliary tract, or pancreatic cancers with homozygous methylthioadenosine phosphorylase (MTAP)-deletion

    phase 1 other active

    1 trial

  15. BEZ235 + MEK162

    Pfizer

    Unspecified Adult Solid Tumor, Protocol Specific

    phase 1 small molecule completed

    1 trial

  16. Master Protocol of Sotorasib (AMG 510) in Subjects with Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101)

    Amgen

    Advanced Solid Tumors Kirsten Rat Sarcoma (KRAS) pG12C Mutation

    phase 1 other active

    1 trial

  17. Valemetostat Tosylate, DS-8201a, Datopotamab deruxtecan, Valemetostat Tosylate, Valemetostat Tosylate

    Daiichi Sankyo

    This study will be a Phase 1b, global, multicenter, open-label, 2-part study of valemetostat in combination with DXd ADCs. The Master Protocol study design contains independent subprotocols, which have been defined by treatment combination and subject population, as follows: Sub-protocol A: Valemetostat in combination with T-DXd in subjects with previously treated, unresectable and/or metastatic HER2-low (immunohistochemistry[IHC] 1+ or IHC 2+/in situ hybridization [ISH]-negative) BC; for details, see Sub-protocol A. Sub-protocol B: Valemetostat in combination with T-DXd in subjects with previously treated, advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma; for details, see Sub-protocol B. Sub-protocol C: Valemetostat in combination with Dato-DXd in subjects with previously treated, locally advanced, unresectable, or metastatic non-squamous NSCLC with or without actionable genomic alteration(s); for details, see Sub-protocol C.

    phase 1 small molecule active

    1 trial

  18. idronoxil

    KAZIA THERAPEUTICS LTD

    Unspecified Adult Solid Tumor, Protocol Specific

    phase 1 small molecule completed

    1 trial

  19. Iohexol 300 mg I/ml solution for injection, MORPHINE (CHLORHYDRATE) RENAUDIN 1 mg/ml, solution injectable

    Tour Hekla

    Evaluation of the CKD-Epi score to identify a glomerular filtration threshold predictive of morphine failure at usual dosage, using a reference method for assessing renal function: iohexol clearance. All other aspects of the protocol are part of standard care practice.

    approved small molecule active

    1 trial

  20. Jakavi 5 mg tablets, Jakavi 10 mg tablets, Jakavi 15 mg tablets, Jakavi 20 mg tablets, Jakavi 5 mg tablets, HDM201, RUXOLITINIB, Jakavi 20 mg tablets, Farydak 15 mg hard capsules, Jakavi 10 mg tablets, Jakavi 15 mg tablets, Jakavi 5 mg tablets, Farydak 10 mg hard capsules, Jakavi 10 mg tablets, Jakavi 15 mg tablets, HDM201, Jakavi 20 mg tablets

    Novartis Pharmaceuticals

    This study is designed to accept patients with varied disease origins, depending on the parent protocol

    approved small molecule active

    1 trial

  21. Surgical tumor resection, GammaTile radiation therapy implantation, Stupp protocol (EBRT and Temozolamide)

    GT Biopharma

    Glioblastoma

    approved other active

    1 trial

  22. XALKORI 200 mg hard capsules, XALKORI 250 mg hard capsules, Crizotinib 200 mg capsules, Crizotinib 250 mg capsules

    Pfizer Australia Pty Ltd

    This Master Protocol for Crizotinib Continuation Sub-Studies has been designed to provide continued treatment access for eligible participants who continue to derive clinical benefit from study intervention in a Pfizer sponsored crizotinib parent study that will be closed

    approved small molecule active

    1 trial

  23. Protocol-based management of perioperative antithrombotic therapy

    The First People's Hospital of Lianyungang

    Antithrombotic Therapy

    small molecule active

    1 trial

  24. Protocol-based management of perioperative antithrombotic therapy

    Peking University Third Hospital

    Antithrombotic Therapy

    small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources